TRAVERE THERAPEUTICS, INC. Accumulated Other Comprehensive Income
TRAVERE THERAPEUTICS, INC. (TVTX) had Accumulated Other Comprehensive Income of -$1.12 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.12M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.06M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.19M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.05M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$1.12M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | -$1.06M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | -$1.19M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | -$1.05M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | -$812.00K 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$843.00K 10-Q · filed 2025-05-01 | |
| 2024-12-31 | -$80.00K 10-K · filed 2026-02-19 | |
| 2024-09-30 | -$1.02M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | -$1.63M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | -$1.89M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | -$1.46M 10-K · filed 2025-02-21 | |
| 2023-09-30 | -$3.65M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$3.85M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$2.18M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$2.91M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $303.00K 10-Q · filed 2022-10-27 | |
| 2022-06-30 | -$1.08M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$1.70M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$562.00K 10-K · filed 2023-02-23 | |
| 2021-09-30 | -$525.00K 10-Q · filed 2021-10-29 | |
| 2021-06-30 | -$641.00K 10-Q · filed 2021-07-29 | |
| 2021-03-31 | -$262.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | -$902.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $354.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.40M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | -$1.50M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $726.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $1.17M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $781.00K 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $57.00K 10-Q · filed 2019-05-07 | |
| 2018-12-31 | -$1.53M 10-K · filed 2020-02-24 | |
| 2018-09-30 | -$1.08M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | -$1.15M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | -$1.53M 10-Q · filed 2018-07-06 | |
| 2017-12-31 | -$1.01M 10-K · filed 2019-02-26 | |
| 2017-09-30 | -$595.00K 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$576.00K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$421.00K 10-Q · filed 2017-05-05 | |
| 2016-12-31 | -$490.00K 10-K · filed 2018-07-06 | |
| 2016-09-30 | -$304.00K 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $21.00K 10-Q · filed 2016-08-05 | |
| 2016-03-31 | -$162.00K 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$682.00K 10-K · filed 2017-03-01 | |
| 2015-09-30 | -$102.00K 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $760.00K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $1.09M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $4.29M 10-K · filed 2016-02-26 | $4.29M 10-K · filed 2015-03-11 |
| 2014-09-30 | $3.74M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $408.90K 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $512.09K 10-Q · filed 2014-05-15 | |
| 2013-12-31 | -$109.99K 10-K/A · filed 2015-07-09 | |
| 2013-09-30 | -$154.83K 10-Q/A · filed 2015-07-09 | |
| 2012-12-31 | $0.00 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |